Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Gentamicin
Drug ID BADD_D01016
Description Gentamicin is a bactericidal aminoglycoside that was discovered and isolated from _Micromonospora purpurea_ in 1963.[A234349] It is one of the most frequently prescribed aminoglycosides due to its spectrum of activity, low cost, and availability.[A234339,A234354] Gentamicin is effective against both gram-positive and gram-negative organisms but is particularly useful for the treatment of severe gram-negative infections including those caused by _Pseudomonas aeruginosa_.[A233325,A234359,A234364] There is the added benefit of synergy when gentamicin is co-administered with other antibacterials such as beta-lactams.[A234364] This synergistic activity is not only important for the treatment of complex infections, but can also contribute to dose optimization and reduced adverse effects.[A234359,A234364] Although gentamicin is well-established and may be used in a variety of clinical applications, it is also associated with severe adverse effects including nephrotoxicity and ototoxicity which may limit its use.[A234369]
Indications and Usage For treatment of serious infections caused by susceptible strains of the following microorganisms: P. aeruginosa, Proteus species (indole-positive and indole-negative), E. coli, Klebsiella-Enterobactor-Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative).
Marketing Status Prescription; Discontinued
ATC Code D06AX07; J01GB03; S01AA11; S02AA14; S03AA06
DrugBank ID DB00798
KEGG ID D08013
MeSH ID D005839
PubChem ID 3467
TTD Drug ID D0L9UU
NDC Product Code 51662-1508; 63323-173
Synonyms Gentamicins | Gentamycins | Garamycin | Gentacycol | Gentamicin Sulfate | Sulfate, Gentamicin | Gentamicin Sulfate (USP) | Gentavet | Genticin | G-Myticin | G Myticin | GMyticin | Gentamicin | Gentamycin
Chemical Information
Molecular Formula C21H43N5O7
CAS Registry Number 1403-66-3
SMILES CC(C1CCC(C(O1)OC2C(CC(C(C2O)OC3C(C(C(CO3)(C)O)NC)O)N)N)N)NC
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
NecrosisSodium/potassium-transporting ATPase subunit alpha-1P05023T408001647125; 1322021; 12905033; 2843053; 1315476; 2563204; 7694338; 11832431
Nephropathy toxicVariant-surface-glycoprotein phospholipase CP09194Not Available6092605; 6307156; 6276533; 3566282; 8663028; 3164751; 2623196; 7876334; 2159723; 8498544; 12039977
Renal impairmentLysosomal Pro-X carboxypeptidaseP42785T20371Not Available
Renal impairmentDipeptidyl aminopeptidase-like protein 6P42658Not AvailableNot Available
Toxicity to various agentsPhospholipase A2P04054T31479Not Available
Toxicity to various agents1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1Q9NQ66T26846Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Oliguria20.01.03.004--Not Available
Ototoxicity12.03.01.012; 04.03.01.0040.014457%Not Available
Oxygen saturation decreased13.02.01.0040.002065%Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Pallor24.03.04.001; 23.03.03.031; 08.01.03.0320.001377%Not Available
Paraesthesia17.02.06.005--
Pathogen resistance11.01.08.0490.000718%Not Available
Peritonitis11.01.07.007; 07.19.05.0040.003442%
Pharyngeal oedema23.04.01.016; 22.04.05.003; 10.01.05.0160.001377%Not Available
Phlebitis24.05.03.001; 12.02.01.002--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pruritus23.03.12.001--
Pulmonary fibrosis22.01.02.006--
Pupillary reflex impaired06.05.03.009; 17.02.11.0070.001377%Not Available
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.0030.014457%
Rash23.03.13.0010.018588%Not Available
Rash erythematous23.03.06.0030.001377%Not Available
Rash maculo-papular23.03.13.0040.002065%
Rash morbilliform23.03.13.0050.001377%Not Available
Renal disorder20.01.02.0020.001377%Not Available
Renal failure20.01.03.0050.002155%Not Available
Renal tubular necrosis20.01.07.0030.005508%Not Available
Respiratory depression22.02.01.010; 17.02.05.047--Not Available
Respiratory distress22.02.01.0120.002065%Not Available
Respiratory failure22.02.06.002; 14.01.04.0030.000359%
Reticulocyte count abnormal13.01.05.019--Not Available
Retinal exudates24.03.07.007; 06.10.02.0030.001377%Not Available
Retinal haemorrhage24.07.05.003; 06.10.01.0010.002065%Not Available
The 5th Page    First    Pre   5 6 7 8    Next   Last    Total 8 Pages